CHENGDU, China, Nov. 6 TianyinPharmaceutical, Co., Inc., (Amex: TPI), a manufacturer and supplier ofmodernized traditional Chinese medicine ("TCM") based in Chengdu, China, todayannounced the appointment of Mr. Tao Yang to the position of Chief Advisor ofSales and Marketing Strategy Committee and special advisor to its CEO toassist optimizing the Company's distribution network and building a stafftraining system.
Mr. Yang is a well-known certified training specialist with more than 18years experience in sales and marketing industry. He started his career as asalesman, marketing manager and a training specialist at Astra Zeneca ofSweden and Bayer of Germany, respectively since 1991. Meanwhile, he alsoreceived systematic training in the US from Learning International, DDI, AMI,Train the Trainer and later became its certified training specialist. He hasbeen an advisor and training specialist for more than 85 domestic andinternational enterprises since 1998 including many pharmaceutical companiessuch as Grunenthal- San Huan Pharmaceutical (China) Co., Ltd., Beaufour IpsenPharmaceutical Co., Ltd., and Yangtze River Pharmacy Group, etc. Mr. Yangalso served as BPIP implementation consultant of CPDF launched by World Banksince 2001, and the executive advisor of a policy system program in 2007,which is a training system formed by the Chinese and British government aimingto support the domestic small to medium size businesses.
Dr. Jiang Guoqing, Tianyin's Chairman and Chief Executive Officer, said,"We are very pleased to have Mr. Yang join as our Chief Advisor of Sales andMarketing Strategy Committee and as my special advisor. As we continue tostrengthen our sales and marketing effort, Mr. Yang's experience will furtherimprove our distribution network as well as build a strong sales and marketingteam. We are confident that the new appointment will help create a strongerorganization and help facilitate our future growth."
About Tianyin Pharmaceuticals
Tianyin is a manufacturer and supplier of modernized Traditional ChineseMedicine ("TCM") in China. It was established in 1994 and acquired by thecurrent management team in August 2003. It has a comprehensive productportfolio of 33 modernized TCMs and 5 generic western medicines in the market,22 of which are listed in the highly selective National Medicine Catalog ofthe National Medical Insurance Program. Tianyin owns and operates two GMPmanufacturing facilities and an R&D platform supported by leading Chineseacademic institutions. The Company has a pipeline of 47 pharmaceuticalproducts pending approval. Tianyin has an extensive nationwide distributionnetwork throughout China with a sales force of 720 salespeople. Tianyin isheadquartered in Chengdu, Sichuan Province with two manufacturing facilitiesand a total of 1,365 employees. Tianyin achieved revenue of approximately$33.5 million and net income of approximately $6 million in FY2008 ending June30, 2008. For more information about Tianyin, please visithttp://www.tianyinpharma.com .
Safe Harbor Statement
The Statements which are not historical facts contained in this pressrelease are forward-looking statements that involve certain risks anduncertainties including but not limited to risks associated with theuncertainty of future financial results, additional financing requirements,development of new products, government approval processes, the impact ofcompetitive products or pricing, technological changes, the effect of economicconditions and other uncertainties detailed in the Company's filings with theSecurities and Exchange Commission.For more information, please contact: For the Company: Allen Tang, Ph.D., MBA, Assistant to the CEO China Tel: +86-158-2122-5642 Email: [email protected]
Investors: Alan Sheinwald HC International, Inc. US Tel: +1-914-669-0222 Email: [email protected]
SOURCE Tianyin Pharmaceutical, Co., Inc.